IN THE CLAIMS

Kindly enter the following amended claim.

Claims 1-46 (canceled)

47. (currently amended) A method for ~~the~~ stimulation of cytotoxicity by NK cells ~~cytotoxicity~~, comprising:
- contacting said NK cells with ~~a sufficient~~ an amount of ~~an isolated~~ antibody ~~according to claim 22, 34 or 36,~~ or a binding fragment thereof, which specifically binds to a polypeptide having at least an amino acid sequence of SEQ ID NO:2, effective to stimulate their cytotoxicity ~~under conditions allowing antibody-mediated cross-linking of NKp30~~.

Claims 48-59 (canceled)

Kindly add the following new claims.

60. (new) The method according to claim 47, wherein said antibody specifically binds to a polypeptide having at least an amino acid sequence of SEQ ID NO:4.

61. (new) The method according to claim 47, wherein said antibody specifically binds to a polypeptide having at least an amino acid sequence of SEQ ID NO:5.

62. (new) The method according to claim 47, wherein said antibody specifically binds to a polypeptide having at least an amino acid sequence of SEQ ID NO:6.

63. (new) The method according to claim 47, wherein said antibody specifically binds to a polypeptide having at least an amino acid sequence of SEQ ID NO:7.

64. (new) The method according to claim 47, wherein said antibody is a polyclonal antibody.

65. (new) The method according to claim 47, wherein said antibody is a monoclonal antibody.

66. (new) The method according to claim 47, wherein said antibody is a humanized mouse monoclonal antibody.

67. (new) The method according to claim 47, wherein said antibody is an antibody of human origin.

68. (new) The method according to claim 65, wherein said monoclonal antibody is produced by hybridoma I-2576.

69. (new) The method according to claim 47, wherein said antibody or binding fragment thereof is coupled to a label.

70. (new) The method according to claim 69, wherein said label is a fluorescent label.

71. (new) The method according to claim 47, wherein said antibody or binding fragment thereof is attached to a solid support.

72. (new) The method according to claim 71, wherein said solid support is selected from the group consisting of paramagnetic microsphere, submicroscopic MACS microbead, semi-permeable substrate consisting of an array of hollow fibers, and dense particle.

73. (new) The method according to claim 65, wherein said monoclonal antibody is selected from the group consisting of AZ20, A76, and Z25.